Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...

Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...

Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the ...

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: When was the last time you recovered money for shareholders?

Stifel-analisten hebben donderdag hun koopadvies en koersdoel van $92,00 voor het aandeel Globus Medical (NYSE: GMED) gehandhaafd na de aankondiging van de overname van Nevro Corp. (NVRO) voor een aan ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Op vrijdag heeft Piper Sandler-analist Adam Maeder het advies voor aandelen van Nevro Corp (NYSE: NVRO ), een medisch technologiebedrijf met een marktkapitalisatie van $214 miljoen, verhoogd van Under ...

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...